Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Non-Current Deferred Tax Liability (2023 - 2025)

Rein Therapeutics (RNTX) has disclosed Non-Current Deferred Tax Liability for 3 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Non-Current Deferred Tax Liability fell 40.18% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, down 40.18% year-over-year, with the annual reading at $1.1 million for FY2025, 40.18% down from the prior year.
  • Non-Current Deferred Tax Liability for Q4 2025 was $1.1 million at Rein Therapeutics, down from $1.8 million in the prior quarter.
  • The five-year high for Non-Current Deferred Tax Liability was $3.3 million in Q4 2023, with the low at $1.1 million in Q4 2025.
  • Average Non-Current Deferred Tax Liability over 3 years is $2.4 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Non-Current Deferred Tax Liability crashed 46.72% in 2024, then crashed 40.18% in 2025.
  • Over 3 years, Non-Current Deferred Tax Liability stood at $3.3 million in 2023, then plummeted by 46.72% to $1.8 million in 2024, then plummeted by 40.18% to $1.1 million in 2025.
  • According to Business Quant data, Non-Current Deferred Tax Liability over the past three periods came in at $1.1 million, $1.8 million, and $1.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.